Merck could see double-digit stock price increases in next 5 years: Jacob Sonenshine
Barron's market reporter Jacob Sonenshine breaks down the market as the Fed meeting kicks off and spotlights pharmaceutical company Merck.
BioPharma Dive26m
ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial
The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.
Investor's Business Daily on MSN11m
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...
KALW38m
Cyberattacks plague health care. Critics call the federal response 'inadequate'
The Change Healthcare cyberattack sparked a new strategy from the federal government on preventing destructive ransomware ...
The Globe and Mail23m
Stocks Move Higher on Strength in Chip Stocks and Positive Corporate News
Also, UnitedHealth Group (UNH) is down more than -2% to lead losers in the Dow Jones industrials. Merck & Co (MRK) is down more than -2% after the latest data from trials of Summit Therapeutics lung ...